Jones Trading Upgrades Editas Medicine (EDIT) to Buy, 'Potentially Best-in-Class Preclinical Data'
Jones Trading analyst Soumit Roy upgraded Editas Medicine (NASDAQ: EDIT) from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)